Puerarin(PUE), an isoflavonoid extracted from Pueraria root, has anti‐apoptotic effects. The objective of this research is to examine the impact of PUE on renal apoptosis and inflammation resulting from renal calculi and to elucidate its mechanism. The approach of network pharmacology and molecular docking was employed to discover potential targets and pathways of PUE. An animal model of calcium oxalate crystal deposition by intraperitoneal injection of glyoxylate and a model of COM‐induced human renal tubular epithelial cells (HK2) were used to investigate the pharmacological mechanisms of PUE against apoptosis and inflammation. We used haematoxylin–eosin (H&E) and Periodic Acid‐Schiff staining (PAS) to assess the effect of PUE on crystal deposition and damage. The mechanism of PUE was elucidated and validated using Western blotting, histology and immunohistochemical staining. Network pharmacology findings indicated that the PI3K/AKT pathway plays a crucial role in PUE. We experimentally demonstrate that PUE alleviated COM‐induced changes in apoptotic proteins, increased inflammatory indicators and changes in oxidative stress‐related indicators in HK2 cells by activating the PI3K/AKT pathway, reduced serum creatinine and urea nitrogen levels in mice caused by CaOx, alleviated crystal deposition and damage, and alleviated apoptosis, oxidative stress and inflammation. Puerarin attenuates renal apoptosis and inflammation caused by kidney stones through the PI3K/AKT pathway.
Purpose. Severe hemorrhage after percutaneous nephrolithotomy (PCNL) is a rare but alerting event. In this study, we report the factors affecting massive hemorrhage after PCNL, various levels of vascular damage during renal angiography, and the therapeutic effect of superselective renal artery embolization (SRAE). Patients and Methods. A retrospective analysis was performed on the data of 69 patients with postoperative PCNL hemorrhage who underwent SRAE from January 2010 to March 2021. Inclusion criteria for all cases were failure of conservative treatment for severe renal hemorrhage after surgery and then treatment with SRAE. In addition, 98 patients without significant hemorrhage after PCNL were randomly selected as the control group. All clinical data are confirmed by imaging and laboratory examinations. We performed univariate and multivariate analyses to find risk factors of massive hemorrhage and high-grade renal vascular injury after PCNL. Results. A total of 69 patients underwent angiography, 64 of which received SRAE due to positive hemorrhages detected by angiography. Urinary tract infection (OR (95 CI)=11.214 (2.80444.842)), high blood pressure (OR (95 CI)=5.686 (1.40123.083)), and no hydronephrosis (OR (95 CI)=0.189 (0.0490.724)) are the most important factors leading to massive hemorrhage after PCNL. In patients who need SRAE after hemorrhage, high-grade vascular injury (grade III) is related to advanced age and decreased hemoglobin. Conclusion. During the perioperative period of PCNL, patients with a risk of hypertension, urinary tract infection, and no hydronephrosis should be strengthened to monitor their high risk of postoperative hemorrhage. For patients with postoperative hemorrhage, we can use the patients age and decreased hemoglobin before and after operation for analysis. In this way, individualized assessment can greatly improve the efficiency of SRAE treatment.
Background: Our objective was to conduct a thorough evaluation of the burden of CKD and its associated anemia by age and sex at the global, regional, and national levels, with projections extending to 2050. Methods: The data from the Global Burden of Diseases (GBD) 2021 were used to describe relevant indicators of CKD and its associated anemia. At different geographic levels, subgroup analysis was carried out by sex, age, and Socio-Demographic Index (SDI). The time trend was examined using the joinpoint regression and decomposition analyses, and predictive analysis was utilized to further estimate the disease burden to 2050. Results: The incidence, prevalence, mortality, and Disability-Adjusted Life Years (DALYs) of CKD, along with the prevalence and Years Lived with Disability (YLDs) of CKD-associated anemia, maintained a steady increase and would continue until 2050. In addition, the ASRs of mortality and DALYs attributable to CKD in 2021 were highest in low SDI regions. Regionally, CKD exhibited the greatest ASRs of mortality and DALYs in Central Latin America in 2021. Meanwhile, the disease burden of CKD and its associated anemia also showed significant differences at different national levels probably mainly due to population growth and aging. Moreover, the prediction analysis showed that the ASR of incidence attributable to CKD continued to increase. Conclusions: With the global population growth and aging, the disease burden of CKD and its associated anemia is still high and varies significantly at the global, regional, and national levels, which requires healthcare professionals to refine targeted interventions.
12 February 2025 in International Immunopharmacology